Failing systemic right ventricle: to treat or not to treat

Published on Jun 4, 2021in Heart5.213
· DOI :10.1136/HEARTJNL-2021-319337
Laura Dos-Subirà5
Estimated H-index: 5
Sources
Abstract
Congenital heart diseases (CHD) are a heterogeneous group of conditions that afflict an increasing number of adults. On some occasions, the singularities of the anatomy and physiology are a real challenge for the treating cardiologist. Such is the case of patients with congenitally corrected transposition of the great arteries (ccTGA) and those with transposition of the great arteries (TGA) repaired with the atrial switch procedure, in which a morphologically right ventricle (RV) sustains the systemic circulation. Although there are case reports of asymptomatic elderly patients being diagnosed with previously undetected ccTGA, these are exceptions. The systemic right ventricle (SRV) usually experiences a progressive decline in the systolic function ultimately leading to death or heart transplantation in most cases. Available drug strategies for the treatment of the failing left ventricle (LV) in acquired heart disease are commonly used in the SRV dysfunction, but such approach is not based on scientific evidence. Several studies have unsuccessfully tried to prove a net benefit from the use of beta blockers or agents targeting the renin-angiotensin-aldosterone system (RAAS) in patients with biventricular circulation and an SRV. Even a few randomised controlled trials (RCT), the top method in the hierarchy of scientific evidence, have failed in this purpose.1 There are different reasons that could explain this lack of success, the most important being the small sample size of all the studies. The largest RCT2 only included 88 patients (44 randomised to valsartan and 44 to placebo). Considering that the Survival And Ventricular Enlargement …
📖 Papers frequently viewed together
53 Citations
5 Citations
25 Citations
References8
Newest
#1Magalie LadouceurH-Index: 21
Last. Konstantinos Dimopoulos (Imperial College London)H-Index: 59
view all 18 authors...
Background To date, clinical trials have been underpowered to demonstrate a benefit from ACE inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) in preventing systemic right ventricle (sRV) failure and disease progression in patients with transposition of the great arteries (TGA). This observational study aimed to estimate the effect of ACEi and ARB on heart failure (HF) incidence and mortality in a large population of patients with an sRV. Methods Data on all patients with an sRV unde...
1 CitationsSource
#1Christoph Haller (U of T: University of Toronto)H-Index: 6
#2Mark K. Friedberg (U of T: University of Toronto)H-Index: 42
Last. Michael A. Laflamme (U of T: University of Toronto)H-Index: 33
view all 3 authors...
Right ventricular (RV) failure is a commonly encountered problem in patients with congenital heart disease but can also be a consequence of left ventricular disease, primary pulmonary hypertension, or RV-specific cardiomyopathies. Improved survival of the aforementioned pathologies has led to increasing numbers of patients suffering from RV dysfunction, making it a key contributor to morbidity and mortality in this population. Currently available therapies for heart failure were developed for th...
1 CitationsSource
Abstract Patients with systemic morphological right ventricles (RVs), including congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries with a Mustard or Senning atrial baffle repair, have a high likelihood of developing systemic ventricular dysfunction. Unfortunately, there are a limited number of clinical studies on the efficacy of medical therapy for systemic RV dysfunction. We performed a systematic review and meta-analysis to assess the effe...
23 CitationsSource
#1Mark K. Friedberg (U of T: University of Toronto)H-Index: 42
#2Andrew N. Redington (U of T: University of Toronto)H-Index: 78
Ventricular failure manifests in many forms, its underlying physiology ranging from overt left ventricular (LV) systolic dysfunction to isolated right ventricular (RV) diastolic dysfunction, and the wide portfolio of resulting symptoms vary from chronic fluid retention to acute multiorgan dysfunction and death. In this review, we discuss the morphological, functional, and molecular similarities and differences in RV and LV responses to adverse loading and failure. We further discuss whether LV a...
172 CitationsSource
#1Laura Dos (Hebron University)H-Index: 11
#2Sandra PujadasH-Index: 15
Last. Jaume Casaldáliga (Hebron University)H-Index: 9
view all 13 authors...
Abstract Background There is no proven pharmacological strategy for the treatment of the failing systemic right ventricle (SRV) but myocardial fibrosis may play a role in its pathophysiology. Methods We designed a double-blind, placebo-controlled clinical trial to assess the effects of eplerenone 50mg during 12months on cardiac magnetic resonance parameters (SRV mass and ejection fraction) and neurohormonal and collagen turnover biomarker (CTB) levels. Results Twenty six patients with atrial swi...
38 CitationsSource
#1Teun van der BomH-Index: 12
#2Michiel M. WinterH-Index: 17
Last. Barbara J.M. MulderH-Index: 77
view all 11 authors...
BACKGROUND: The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. METHODS AND RESULTS: We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular eject...
136 CitationsSource
#1Jayan Nagendran (U of A: University of Alberta)H-Index: 22
#2Stephen L. Archer (U of C: University of Chicago)H-Index: 102
Last. Evangelos D. Michelakis (U of A: University of Alberta)H-Index: 77
view all 13 authors...
Background— Sildenafil was recently approved for the treatment of pulmonary arterial hypertension. The beneficial effects of phosphodiesterase type 5 (PDE5) inhibitors in pulmonary arterial hypertension are thought to result from relatively selective vasodilatory and antiproliferative effects on the pulmonary vasculature and, on the basis of early data showing lack of significant PDE5 expression in the normal heart, are thought to spare the myocardium. Methods and Results— We studied surgical sp...
456 CitationsSource
#1Marc A. PfefferH-Index: 187
#2Eugene BraunwaldH-Index: 266
Last. C. Morton HawkinsH-Index: 22
view all 18 authors...
Abstract Background. Left ventricular dilatation and dysfunction after myocardial infarction are major predictors of death. In experimental and clinical studies, long-term therapy with the angiotensin-converting—enzyme inhibitor captopril attenuated ventricular dilatation and remodeling. We investigated whether captopril could reduce morbidity and mortality in patients with left ventricular dysfunction after a myocardial infarction. Methods. Within 3 to 16 days after myocardial infarction, 2231 ...
1,065 CitationsSource
Cited By0
Newest